These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1761640)

  • 1. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection.
    Vanham G; Kestens L; Penne G; Goilav C; Gigase P; Colebunders R; Vandenbruaene M; Goeman J; van der Groen G; Ceuppens JL
    J Clin Immunol; 1991 Nov; 11(6):345-56. PubMed ID: 1761640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens.
    Ho HN; Hultin LE; Mitsuyasu RT; Matud JL; Hausner MA; Bockstoce D; Chou CC; O'Rourke S; Taylor JM; Giorgi JV
    J Immunol; 1993 Apr; 150(7):3070-9. PubMed ID: 8454874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
    Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection.
    Kestens L; Vanham G; Gigase P; Young G; Hannet I; Vanlangendonck F; Hulstaert F; Bach BA
    AIDS; 1992 Aug; 6(8):793-7. PubMed ID: 1418775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection.
    Prince HE; Jensen ER
    J Acquir Immune Defic Syndr (1988); 1991; 4(12):1227-32. PubMed ID: 1719188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.
    Kestens L; Vanham G; Vereecken C; Vandenbruaene M; Vercauteren G; Colebunders RL; Gigase PL
    Clin Exp Immunol; 1994 Mar; 95(3):436-41. PubMed ID: 7907956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study.
    Giorgi JV; Liu Z; Hultin LE; Cumberland WG; Hennessey K; Detels R
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):904-12. PubMed ID: 7686224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells.
    Ramzaoui S; Jouen-Beades F; Gilbert D; Borsa-Lebas F; Michel Y; Humbert G; Tron F
    Clin Immunol Immunopathol; 1995 Oct; 77(1):33-41. PubMed ID: 7554481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes.
    Mahalingam M; Pozniak A; McManus TJ; Vergani D; Peakman M
    Clin Exp Immunol; 1995 Dec; 102(3):481-6. PubMed ID: 8536361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.
    Bofill M; Mocroft A; Lipman M; Medina E; Borthwick NJ; Sabin CA; Timms A; Winter M; Baptista L; Johnson MA; Lee CA; Phillips AN; Janossy G
    AIDS; 1996 Jul; 10(8):827-34. PubMed ID: 8828739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.
    Giorgi JV; Ho HN; Hirji K; Chou CC; Hultin LE; O'Rourke S; Park L; Margolick JB; Ferbas J; Phair JP
    J Infect Dis; 1994 Oct; 170(4):775-81. PubMed ID: 7930717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.
    Aldhous MC; Watret KC; Mok JY; Bird AG; Froebel KS
    Clin Exp Immunol; 1994 Jul; 97(1):61-7. PubMed ID: 8033422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.
    Watret KC; Whitelaw JA; Froebel KS; Bird AG
    Clin Exp Immunol; 1993 Apr; 92(1):93-9. PubMed ID: 7682164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.
    Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT
    Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects.
    Vanham G; Kestens L; De Meester I; Vingerhoets J; Penne G; Vanhoof G; Scharpé S; Heyligen H; Bosmans E; Ceuppens JL
    J Acquir Immune Defic Syndr (1988); 1993 Jul; 6(7):749-57. PubMed ID: 8099610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens.
    Echaniz P; Arrizabalaga J; Iribarren JA; Cuadrado E
    Cell Immunol; 1993 Aug; 150(1):72-80. PubMed ID: 7688270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable.
    Froebel KS; Raab GM; D'Alessandro C; Armitage MP; MacKenzie KM; Struthers M; Whitelaw JM; Yang S
    Clin Exp Immunol; 2000 Oct; 122(1):72-8. PubMed ID: 11012621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.
    Ferbas J; Kaplan AH; Hausner MA; Hultin LE; Matud JL; Liu Z; Panicali DL; Nerng-Ho H; Detels R; Giorgi JV
    J Infect Dis; 1995 Aug; 172(2):329-39. PubMed ID: 7622874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.